Today, the 2016 Shenzhen International BT Leaders Summit and the Bio/Life Health Industry Exhibition will be held at the Shenzhen Convention and Exhibition Center. Both the exhibition site and the summit forum will see the “body figure†of the municipal public hospital.
Because there is no platform for colleges and universities, scientific research has always been the "short board" of hospitals in our city. With the help of “three projectsâ€, the municipal public hospitals actively cooperate with high-level medical research institutions and discipline teams at home and abroad to create medical innovation platforms such as precision medicine , biomedicine, translational medicine and traditional Chinese medicine, and promote the rapid transformation of basic medical and clinical research results into clinical practice. Apply new technologies, new methods and new products to promote regenerative medicine such as tissue engineering, cell and cytokine therapy, gene therapy, microecological therapy, and clinical application of 3D visualization and 3D printing technologies, and rapidly improve the high-end medical technology level of our city. .
â— Regulatory genes make cancer cells "suicide"
The CRISPR-Cas9 gene editing system is called "gene editing" by the scientific community because of its powerful gene editing and regulation capabilities. The 973 project team of Shenzhen Second People's Hospital improved and perfected the deficiencies of the CRISPR-Cas9 gene editing system, and realized the manipulation of Cas9, thus achieving targeted intervention of cancer cells. Recently, one of Nature's most important journals, Nature and Methodology, released the major research results of the institute, which has attracted the attention of the global medical profession.
Shenzhen has made such a significant progress in the basic research of cancer precision treatment thanks to the “three projectsâ€. In the first batch of “three projectsâ€, the Second Hospital of the City and Dr. Zhao Guoping’s oncology precision treatment team cooperated to establish the “Shenzhen Medical Reprogramming Technology Key Laboratory†research work platform, in liquid biopsy technology, gene editing technology, Research work on immune cell reprogramming and other technologies to achieve accurate prediction, prevention, treatment and prognosis of diseases. The research results released by Nature and Methodology are one of the achievements of this project.
â—Nano-ultrasound contrast agent "direct" tumor
The Department of Ultrasound Imaging, Peking University Shenzhen Hospital introduced the “Team of Professor Wang Jinrui from Peking University Third Hospital†and established the “Infrared Intervention and Molecular Imaging Center of Peking University Shenzhen Hospital†to jointly develop a new nano-ultrasound contrast agent.
This kind of contrast agent can penetrate the tumor tissue through the blood vessel, and it is more convenient to find the early tumor. It can also carry the specific drug directly to the tumor target through nano-ultrasound contrast agent, and direct release under the guidance of ultrasound to realize the tumor. Accurate, targeted, non-invasive treatment greatly expands the clinical application of ultrasound, bringing new tools for early diagnosis and precision treatment of tumors.
At present, the research has achieved that the ultrasound microbubble targeted rupture breaks through the blood-brain barrier and directly delivers the drug to the brain. It is expected that the results will be applied clinically within 3-5 years.
â—Innovative platform to prevent and control infectious diseases
The Third People's Hospital of the city has introduced a number of “three engineering†teams, and has repeatedly made breakthroughs in the prevention and control of infectious diseases.
In cooperation with the team of Academician Gao Fu, the “Shenzhen Key Laboratory of Pathogenic Microorganisms and Immunology†was established, and the specimen bank and cell bank were built, and a new infectious disease pathogen monitoring platform was established. This platform is of great significance for the prevention and control of infectious diseases, and it can guarantee that once new cases appear in Shenzhen, they can be processed immediately. In terms of medical conversion, the tuberculosis diagnostic patent product developed by the team, the M. tuberculosis effect T cell test kit, has been approved by the national SFDA and entered the clinical application stage.
Together with the team of Academician Cheng Jing, the "Shenzhen Biochip Research Key Laboratory" has been set up to complete the biochip detection platform for the identification of mycobacterial species, detection of drug resistance genes of Mycobacterium tuberculosis, detection of respiratory pathogens, and nine items. Hereditary deafness gene detection.
Together with the team of Professor Jin Qi (the chief scientist of 973), the “Shenzhen Tuberculosis Research and Engineering Technology Research and Development Center†was established, and a rapid immunodiagnostic method for active tuberculosis and an evaluation index system for anti-tuberculosis treatment efficacy were established.
We're Professional Supplier Extract Powder manufacturers and suppliers in China specialized in providing high-quality products at low price. We warmly welcome you to buy or wholesale bulk Supplier Extract Powder for sale here from our factory. For a free sample, contact us now.
Supplier Extract Powder,Supplier Extract ,Supplier Powder Manufacturer in China
Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.anabolicsteriod.com